Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 22
1984 1
1985 59
1986 240
1987 385
1988 477
1989 610
1990 809
1991 1025
1992 965
1993 1114
1994 1147
1995 1249
1996 1057
1997 965
1998 1004
1999 1086
2000 1212
2001 1183
2002 1216
2003 1470
2004 1529
2005 1692
2006 1924
2007 1691
2008 1801
2009 1777
2010 1857
2011 2419
2012 2800
2013 2810
2014 2586
2015 2582
2016 2132
2017 1931
2018 1617
2019 705
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

45,280 results
Results by year
Filters applied: . Clear all
Page 1
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
Thomas J, et al. Mol Genet Metab 2018 - Clinical Trial. PMID 29653686 Free article.
Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is a potential enzyme substitution therapy to lower blood Phe in adults with PKU. ...
Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammo …
Structural characterization of recombinant therapeutic proteins by circular dichroism.
Bertucci C, et al. Curr Pharm Biotechnol 2011 - Review. PMID 21542799
Most of the protein therapeutics are now produced by recombinant DNA technology. The advantages of recombinant proteins are related to their higher specificity and to their safety as exposure to animal or human diseases. However, several problems are still present in development of recombinant proteins as therapeutics, such as low bioavailability, short serum half-life, and immune response. ...
Most of the protein therapeutics are now produced by recombinant DNA technology. The advantages of recombinant proteins are re …
Cerliponase Alfa: First Global Approval
Markham A. Drugs 2017 - Review. PMID 28589525
Cerliponase alfa (Brineura™) is a recombinant human tripeptidyl peptidase-1 (TPP1) being developed by BioMarin Pharmaceutical Inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1. ...
Cerliponase alfa (Brineura™) is a recombinant human tripeptidyl peptidase-1 (TPP1) being developed by BioMarin Pharmaceutical Inc. fo …
Acute Management of Hereditary Angioedema Attacks
Katelaris CH. Immunol Allergy Clin North Am 2017 - Review. PMID 28687108
Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article. ...
Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewe …
[Advances of long-acting recombinant protein therapeutics].
Wei Y, et al. Sheng Wu Gong Cheng Xue Bao 2018 - Review. PMID 29577686 Chinese. Free article.
Some of the recombinant protein therapeutics with short half-life requires high frequent dose or injection, which results in poor patient compliance. This challenge has prompted the development of long-acting recombinant proteins in recent years. Four strategies and methods, including chemical modification, protein engineering, fusion proteins and protein glycosylation are used to modify protein molecule and finally obtain improved pharmacokinetics (PK) properties. ...
Some of the recombinant protein therapeutics with short half-life requires high frequent dose or injection, which results in poor pat …
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial
Harding CO, et al. Mol Genet Metab 2018 - Clinical Trial. PMID 29628378 Free article.
INTRODUCTION: Pegvaliase is a recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL) enzyme under investigation for treatment of adult phenylketonuria (PKU). ...
INTRODUCTION: Pegvaliase is a recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL) enzyme under investigation for treatm …
Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system.
Brooks SA. Mol Biotechnol 2004 - Review. PMID 15542924
The glycosylation of recombinant proteins, especially those destined for potential administration to human subjects, is of critical importance. ...
The glycosylation of recombinant proteins, especially those destined for potential administration to human subjects, is of critical i …
45,280 results
Jump to page
Feedback